Effect of the calcium channel blocker nisoldipine on the progression of chronic renal failure in man.
Patients with stable renal insufficiency were randomized into two groups: (1) patients given the channel blocker nisoldipine (n = 17) and (2) placebo-treated patients (n = 17) also taking their regular antihypertensive therapy which did not include calcium blockers. Patients were already on low protein diet with a protein intake of 0.80 +/- 0.2 in the nisoldipine group versus 0.85 +/- 0.25 g/kg body weight in the placebo-treated group. The monthly progression of their renal failure was assessed by the reciprocal of serum creatinine versus time in months. After a mean follow-up of 17.4 +/- 8.2 (range 6-30) months, the nisoldipine-treated group had a significant decrease in their slope of progression, whereas the placebo-treated patients, after 16.94 +/- 7.2 (range 6-30) months of follow-up, had no significant change in their slope. The protein intake during follow-up was similar, being 0.85 +/- 0.2 g/kg actual body weight in the nisoldipine-treated group and 0.88 +/- 0.26 g/kg in the placebo group. The changes in slope did not correlate with the changes in blood pressure.
Eliahou
H E
HE
Department of Nephrology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Cohen
D
D
Hellberg
B
B
Ben-David
A
A
Herzog
D
D
Shechter
P
P
Kapuler
S
S
Kogan
N
N
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D004044:Dietary Proteins; D002149:Energy Intake; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D015737:Nisoldipine
D002121:Calcium Channel Blockers; D004044:Dietary Proteins; D015737:Nisoldipine; D009543:Nifedipine